Delta Sleep-Inducing Peptide (DSIP)
Also known as: Emideltide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Delta Sleep-Inducing Peptide (DSIP), also called Emideltide or Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, is a neuropeptide research in the Neuromodulator class. Delta sleep-inducing peptide is a nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep, and named for that association.
For research use only.
Key Facts
- CAS
- 62568-57-4
- Molecular Weight (MW)
- 848.81 g/mol
- Half-life
- ~7-15 minutes
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- Yes
- Administration Route
- Intravenous
- Frequency
- Single administrations in the published studies
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Sleep-regulatory networks (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 32
- Listed offers
- 42
- Median price per mg
- $7.10/mg
- Typical $6.00–$10.00/mg
Research summary
Nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reported effects on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier is debated. Research use only and not FDA-approved.
Peptide Library's Delta Sleep-Inducing Peptide (DSIP) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Delta Sleep-Inducing Peptide (DSIP) dosage chart
Delta sleep-inducing peptide has been given to humans in a series of small European studies from the late 1980s and 1990s, typically as an intravenous dose around 25 nmol/kg. Those studies are the only human dosing evidence, several of them reported no effect on the endocrine endpoints measured, and no trial has been registered or published since. There is no approved product and no established regimen.
| Human dosing established | Yes |
|---|---|
| Studied dose range | About 25 nmol/kg intravenously (weight-based) |
| Route | Intravenous |
| Frequency | Single administrations in the published studies |
| Duration studied | Short study protocols |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Chronic insomnia study (1992)Clinical trial · Placebo-controlled clinical study | Chronic insomniac patients | 25 nmol/kg body weight | Intravenous | In the afternoon before the 3rd, 4th and 5th night | Three administrations across a sleep-laboratory protocol | Sleep architecture | Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. Neuropsychobiology. 1992. |
| Endocrine response study (1993)Clinical trial · Controlled endocrine study with a negative result | Human volunteers | Per study protocol | Intravenous | — | — | Growth hormone and other endocrine responses — no influence found | Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion. Psychoneuroendocrinology. 1993. |
| Anaesthesia study (2009)Clinical trial · Clinical study | Surgical patients | Per study protocol | Intravenous | — | — | Bispectral index and electroencephalogram changes | Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009. |
| Opioid detoxification, open clinical trial (1998)Clinical trial · Open clinical trial | Patients undergoing opioid detoxification | Per study protocol | Intravenous | — | — | Withdrawal symptoms | Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol. 1998. |
Where sources disagree
- The published human dose is weight-based and intravenous, around 25 nmol/kg. DSIP is sold for subcutaneous injection with fixed protocols commonly quoted at 100–500 mcg; those figures do not come from the published studies and the route differs.
- Several of the human studies are explicitly negative — DSIP did not influence growth hormone, prolactin, or meal-induced ACTH and cortisol responses. Secondary sources frequently cite this literature as support for hormonal or recovery benefits without noting that the measured endpoints did not change.
- The human literature is largely three decades old and was not followed by registered trials. Absence of newer evidence is not evidence of a dose.
Reconstitution
Common research vial sizes: 5 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- 3 mL BAC for 5 mg vial
- Injection Sites
- AbdomenThigh
- Concentration Example
- 5 mg / 3 mL = ~1.67 mg/mL
- Timing Notes
- 30-60 min before bed
- Expected Onset
- Days
How to reconstitute Delta Sleep-Inducing Peptide (DSIP)
- Check the vial size and diluent volume. The profile example for Delta Sleep-Inducing Peptide (DSIP) is: 3 mL BAC for 5 mg vial.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 5 mg / 3 mL = ~1.67 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Open the peptide calculator with the Delta Sleep-Inducing Peptide (DSIP) preset →
Sequence & molecular data
| Amino acid sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu |
|---|---|
| Molecular formula | C35H48N10O15 |
| Molecular weight | 848.81 g/mol |
| CAS number | 62568-57-4 |
| Half-life | ~7-15 minutes |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 68816 |
| FDA UNII | YN28Z5YZ73 |
| ChEMBL | CHEMBL2104403 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Delta sleep-inducing peptide is a nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep, and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reports of its effect on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier after peripheral administration is debated. Proposed activities include modulation of GABAergic transmission, influence on circadian and neuroendocrine rhythms including corticotropin and growth hormone release, and stress-buffering effects. For a reference entry the honest position is that the peptide is real and studied but its mechanism is not established.
Origin
Synthetic nonapeptide corresponding to delta sleep-inducing peptide.
Targets
Studies
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
- Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia
- Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs
Regulatory & research status
Delta Sleep-Inducing Peptide (DSIP) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Delta Sleep-Inducing Peptide (DSIP) side effects
Delta Sleep-Inducing Peptide (DSIP) has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Headache
- Vivid dreams (anecdotal)
- Unknown chronic safety
Contraindications
- Psychiatric disorders
Stacking
Common stacking partners
Combinations that include Delta Sleep-Inducing Peptide (DSIP), with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Delta Sleep-Inducing Peptide (DSIP): frequently asked questions
What is Delta Sleep-Inducing Peptide (DSIP)?
Nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reported effects on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier is debated. Research use only and not FDA-approved.
What are the side effects of Delta Sleep-Inducing Peptide (DSIP)?
Delta Sleep-Inducing Peptide (DSIP) has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include headache and vivid dreams (anecdotal). Cautions recorded on this profile: psychiatric disorders. This is reference information, not medical advice.
How does Delta Sleep-Inducing Peptide (DSIP) work?
Delta sleep-inducing peptide is a nonapeptide first isolated from the cerebral venous blood of rabbits during induced slow-wave sleep, and named for that association. Its physiological role remains genuinely unsettled: no specific receptor has been identified, reports of its effect on sleep architecture are inconsistent across studies, and its ability to cross the blood-brain barrier after peripheral administration is debated.
Is Delta Sleep-Inducing Peptide (DSIP) FDA approved?
No. Delta Sleep-Inducing Peptide (DSIP) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Delta Sleep-Inducing Peptide (DSIP)?
Reported half-life for Delta Sleep-Inducing Peptide (DSIP) is ~7-15 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Delta Sleep-Inducing Peptide (DSIP)?
Delta Sleep-Inducing Peptide (DSIP) has the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, giving a chain of 9 amino acids. Its molecular formula is C35H48N10O15.
What peptides are similar to Delta Sleep-Inducing Peptide (DSIP)?
Compounds most often compared with Delta Sleep-Inducing Peptide (DSIP) include Orexin-A, Epitalon, N-Acetyl Selank Amidate and Noopept. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
How long does Delta Sleep-Inducing Peptide (DSIP) take to show effects in research protocols?
The research protocol on this profile lists an expected onset of days. This is a protocol note describing when studies and researchers report observing changes, not a measured clinical outcome, and it varies with the model, dose and endpoint studied.
Where is Delta Sleep-Inducing Peptide (DSIP) administered in research protocols?
Research protocols on this profile use subcutaneous administration, with recorded sites including abdomen, thigh. Site rotation and sterile technique are standard practice in the research literature; this describes protocol conditions and is not guidance for use.
Does DSIP work as a sleep aid?
Not reliably, on current evidence. DSIP was named in the 1970s after rabbit experiments associated it with delta-wave sleep, and the name has outrun the data: human sleep findings have been inconsistent, and it is not established as a sleep-inducing agent. The name describes what its discoverers were looking for, not a demonstrated effect.
Does DSIP cross the blood-brain barrier?
Poorly, like most peptides, which matters for a compound expected to act on sleep. Recent research includes delivery strategies and fusion constructs designed to get DSIP into the brain in rodent insomnia models. That the delivery problem is still being worked on says a lot about how unsettled the basic effect is.
Is DSIP related to melatonin?
No. Melatonin is a hormone made from tryptophan in the pineal gland; DSIP is a nine-amino-acid peptide. They are different molecules acting through different systems, and DSIP is not a melatonin analogue or precursor.
References
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study — Neuropsychobiology, 1992External reference
- Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men — Horm Res, 1994External reference
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle — J Neurochem, 2006External reference
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia — Eur Neurol, 1987External reference
- Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs — Int J Clin Pharmacol Res, 1987External reference
Related research, comparisons & guides
- Peptides for Sleep: Three Candidates, Very Little Evidence
- Cognitive and nootropic peptidesCategory
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the Delta Sleep-Inducing Peptide (DSIP) preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 6
This Delta Sleep-Inducing Peptide (DSIP) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Delta Sleep-Inducing Peptide (DSIP) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →